0001140361-16-083653.txt : 20161026
0001140361-16-083653.hdr.sgml : 20161026
20161026164127
ACCESSION NUMBER: 0001140361-16-083653
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161024
FILED AS OF DATE: 20161026
DATE AS OF CHANGE: 20161026
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Raptor Pharmaceutical Corp
CENTRAL INDEX KEY: 0001070698
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 860883978
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 HAMILTON LANDING
STREET 2: SUITE 100
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-408-6200
MAIL ADDRESS:
STREET 1: 7 HAMILTON LANDING
STREET 2: SUITE 100
CITY: NOVATO
STATE: CA
ZIP: 94949
FORMER COMPANY:
FORMER CONFORMED NAME: Raptor Pharmaceutical Corp.
DATE OF NAME CHANGE: 20090929
FORMER COMPANY:
FORMER CONFORMED NAME: TorreyPines Therapeutics, Inc.
DATE OF NAME CHANGE: 20061003
FORMER COMPANY:
FORMER CONFORMED NAME: AXONYX INC
DATE OF NAME CHANGE: 19990303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Happel David
CENTRAL INDEX KEY: 0001623567
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-25571
FILM NUMBER: 161953067
MAIL ADDRESS:
STREET 1: 7 HAMILTON LANDING
STREET 2: SUITE 100
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2016-10-24
1
0001070698
Raptor Pharmaceutical Corp
RPTP
0001623567
Happel David
C/O RAPTOR PHARMACEUTICAL CORP.
7 HAMILTON LANDING, SUITE 100
NOVATO
CA
94949
0
1
0
0
Chief Commercial Officer
Common Stock
2016-10-24
4
U
0
8934
9.00
D
28939
D
Common Stock
2016-10-25
4
D
0
28939
9.00
D
0
D
Stock Option (right to buy)
3.74
2016-10-25
4
D
0
93784
D
2026-02-09
Common Stock
93784
0
D
Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
/s/ Sally Brammell, as Attorney-in-Fact
2016-10-25